info@marketresearchfuture.com   ๐Ÿ“ž  +1 (855) 661-4441(US)   ๐Ÿ“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Pompe Disease Treatment Market Research Report Information By Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease and Non-Classic infantile-onset Pompe Disease), By Therapy (Gene Therapy and Enzyme Replacement Therapy), By End-User (Hospitals and Clinics and Research and Academic Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) โ€“Market Forecast Till 2032


ID: MRFR/HC/6761-CR | 123 Pages | Author: Rahul Gotadki| January 2020

Market Segmentation


Pompe Disease Treatment Type Outlook (USD Billion, 2018-2032)




  • Late-Onset Pompe Disease




  • Classic Infantile-Onset Pompe Disease




  • Non-Classic infantile-onset Pompe Disease




Pompe Disease Treatment Therapy Outlook (USD Billion, 2018-2032)




  • Gene Therapy




  • Enzyme Replacement Therapy




Pompe Disease Treatment End-User Outlook (USD Billion, 2018-2032)




  • Hospitals And Clinics




  • Research And Academic Institutes




Pompe Disease Treatment Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • North America Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • North America Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • North America Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • US Outlook (USD Billion, 2018-2032)




    • US Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • US Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • US Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Canada Outlook (USD Billion, 2018-2032)




    • Canada Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Canada Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Canada Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes








  • Europe Outlook (USD Billion, 2018-2032)




    • Europe Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Europe Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Europe Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Germany Outlook (USD Billion, 2018-2032)




    • Germany Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Germany Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Germany Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • France Outlook (USD Billion, 2018-2032)




    • France Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • France Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • France Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • UK Outlook (USD Billion, 2018-2032)




    • UK Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • UK Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • UK Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Italy Outlook (USD Billion, 2018-2032)




    • Italy Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Italy Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Italy Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Spain Outlook (USD Billion, 2018-2032)




    • Spain Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Spain Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Spain Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Rest Of Europe Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Rest Of Europe Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Rest Of Europe Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Asia-Pacific Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Asia-Pacific Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Asia-Pacific Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • China Outlook (USD Billion, 2018-2032)




    • China Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • China Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • China Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Japan Outlook (USD Billion, 2018-2032)




    • Japan Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Japan Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Japan Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • India Outlook (USD Billion, 2018-2032)




    • India Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • India Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • India Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Australia Outlook (USD Billion, 2018-2032)




    • Australia Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Australia Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Australia Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Rest of Asia-Pacific Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Rest of Asia-Pacific Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Rest of Asia-Pacific Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Rest of the World Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Rest of the World Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Rest of the World Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Middle East Outlook (USD Billion, 2018-2032)




    • Middle East Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Middle East Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Middle East Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Africa Outlook (USD Billion, 2018-2032)




    • Africa Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Africa Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Africa Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes






    • Latin America Outlook (USD Billion, 2018-2032)




    • Latin America Pompe Disease Treatment by Type




      • Late-Onset Pompe Disease




      • Classic Infantile-Onset Pompe Disease




      • Non-Classic infantile-onset Pompe Disease






    • Latin America Pompe Disease Treatment by Therapy




      • Gene Therapy




      • Enzyme Replacement Therapy






    • Latin America Pompe Disease Treatment by End-User




      • Hospitals And Clinics




      • Research And Academic Institutes







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 13

2.2 RESEARCH OBJECTIVE 13

2.3 MARKET STRUCTURE 13

2.4 ASSUMPTIONS & LIMITATIONS 14

3 RESEARCH METHODOLOGY

3.1 DATA MINING 15

3.2 SECONDARY RESEARCH 16

3.3 PRIMARY RESEARCH 17

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 18

3.5 FORECASTING TECHNIQUES 19

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 20

3.6.1 BOTTOM-UP APPROACH 20

3.6.2 TOP-DOWN APPROACH 21

3.7 DATA TRIANGULATION 21

3.8 VALIDATION 21

4 MARKET DYNAMICS

4.1 OVERVIEW 22

4.2 DRIVERS 23

4.2.1 INCREASING GOVERNMENT INITIATIVES 23

4.2.2 RISING R&D ACTIVITIES BY MANUFACTURERS 23

4.3 RESTRAINTS 24

4.3.1 HIGH COST OF TREATMENT 24

4.4 OPPORTUNITIES 25

4.4.1 EMERGENCE OF IMMUNOTHERAPEUTIC APPROACHES 25

4.5 CHALLENGES 25

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS 26

5.1.1 R&D AND DESIGNING 27

5.1.2 MANUFACTURING 27

5.1.3 DISTRIBUTION & SALES 27

5.1.4 POST-SALES SERVICES 27

5.2 PORTERโ€™S FIVE FORCES MODEL 28

5.2.1 BARGAINING POWER OF SUPPLIERS 29

5.2.2 BARGAINING POWER OF BUYERS 29

5.2.3 THREAT OF NEW ENTRANTS 29

5.2.4 THREAT OF SUBSTITUTES 29

5.2.5 INTENSITY OF RIVALRY 29

6 POMPE DISEASE TREATMENT MARKET, BY TYPE

6.1 OVERVIEW 30

6.2 LATE-ONSET POMPE DISEASE 31

6.3 CLASSIC INFANTILE-ONSET POMPE DISEASE 31

6.4 NON-CLASSIC INFANTILE-ONSET POMPE DISEASE 32

7 POMPE DISEASE TREATMENT MARKET, BY THERAPY

7.1 OVERVIEW 33

7.2 ENZYME REPLACEMENT THERAPY (ERT) 34

7.3 GENE THERAPY 34

7.4 OTHERS 34

8 POMPE DISEASE TREATMENT MARKET, BY END USER

8.1 OVERVIEW 35

8.2 HOSPITALS & CLINICS 36

8.3 RESEARCH & ACADEMIC INSTITUTES 36

9 GLOBAL POMPE DISEASE TREATMENT MARKET, BY REGION

9.1 OVERVIEW 37

9.2 AMERICAS 39

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.2.1 NORTH AMERICA 40

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.2.1.1 US 42

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.2.1.2 CANADA 43

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.2.2 SOUTH AMERICA 44

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.3 EUROPE 46

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.3.1 GERMANY 48

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.3.2 FRANCE 49

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.3.3 UK 50

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.3.4 ITALY 51

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.3.5 SPAIN 52

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.3.6 REST OF EUROPE 53

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.4 ASIA-PACIFIC 54

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.4.1 CHINA 56

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.4.2 JAPAN 57

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.4.3 INDIA 58

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.4.4 SOUTH KOREA 59

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.4.5 AUSTRALIA 60

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.4.6 REST OF ASIA-PACIFIC 61

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.5 MIDDLE EAST & AFRICA 62

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.5.1 MIDDLE EAST 63

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

9.5.2 AFRICA 64

POMPE DISEASE TREATMENT MARKET, BY TYPE

POMPE DISEASE TREATMENT MARKET, BY THERAPY

POMPE DISEASE TREATMENT MARKET, BY END USER

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW 66

10.2 MAJOR PLAYERS IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 66

10.3 COMPETITIVE BENCHMARKING 67

10.4 COMPETITOR DASHBOARD 68

10.5 MAJOR GROWTH STRATEGY IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 69

10.6 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL POMPE DISEASE TREATMENT

MARKET 69

10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 70

10.7.1 EXPANSION 70

10.7.2 ANNOUNCEMENT 71

10.7.3 PATENT 71

10.7.4 DEVELOPMENTS 71

10.7.5 DEFINITIVE AGREEMENT 71

11 COMPANY PROFILES

11.1 AMICUS THERAPEUTICS, INC 72

11.1.1 COMPANY OVERVIEW 72

11.1.2 FINANCIAL OVERVIEW 72

11.1.3 PRODUCTS/SERVICES OFFERED 72

11.1.4 KEY DEVELOPMENTS 73

11.1.5 SWOT ANALYSIS 73

11.1.6 KEY STRATEGIES 73

11.2 SANOFI 74

11.2.1 COMPANY OVERVIEW 74

11.2.2 FINANCIAL OVERVIEW 74

11.2.3 PRODUCTS/SERVICES OFFERED 75

11.2.4 KEY DEVELOPMENTS 75

11.2.5 SWOT ANALYSIS 76

11.2.6 KEY STRATEGIES 76

11.3 AUDENTES THERAPEUTICS 77

11.3.1 COMPANY OVERVIEW 77

11.3.2 FINANCIAL OVERVIEW 77

11.3.3 PRODUCTS/SERVICES OFFERED 77

11.3.4 KEY DEVELOPMENTS 78

11.3.5 SWOT ANALYSIS 78

11.3.6 KEY STRATEGIES 78

11.4 OXYRANE 79

11.4.1 COMPANY OVERVIEW 79

11.4.2 FINANCIAL OVERVIEW 79

11.4.3 PRODUCTS/SERVICES OFFERED 79

11.4.4 KEY DEVELOPMENTS 79

11.4.5 SWOT ANALYSIS 80

11.4.6 KEY STRATEGIES 80

11.5 VALERION THERAPEUTICS 81

11.5.1 COMPANY OVERVIEW 81

11.5.2 FINANCIAL OVERVIEW 81

11.5.3 PRODUCTS/SERVICES OFFERED 81

11.5.4 KEY DEVELOPMENTS 81

11.5.5 SWOT ANALYSIS 82

11.5.6 KEY STRATEGIES 82

11.6 AVROBIO, INC. 83

11.6.1 COMPANY OVERVIEW 83

11.6.2 FINANCIAL OVERVIEW 83

11.6.3 PRODUCTS/SERVICES OFFERED 84

11.6.4 KEY DEVELOPMENTS 84

11.6.5 SWOT ANALYSIS 84

11.6.6 KEY STRATEGIES 84

11.7 CENTOGENE AG 85

11.7.1 COMPANY OVERVIEW 85

11.7.2 FINANCIAL OVERVIEW 85

11.7.3 PRODUCTS/SERVICES OFFERED 85

11.7.4 KEY DEVELOPMENTS 85

11.7.5 SWOT ANALYSIS 86

11.7.6 KEY STRATEGIES 86

12 APPENDIX

12.1 REFERENCES 87

12.2 RELATED REPORTS 87

13 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 14

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 17

TABLE 3 GLOBAL POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 30

TABLE 4 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR LATE-ONSET POMPE DISEASE, BY REGION 2016โ€“2030 (USD MILLION) 31

TABLE 5 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016โ€“2030

(USD MILLION) 31

TABLE 6 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR NON-CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016โ€“2030

(USD MILLION) 32

TABLE 7 GLOBAL POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 33

TABLE 8 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR ENZYME REPLACEMENT THERAPY (ERT), BY REGION 2016โ€“2030

(USD MILLION) 34

TABLE 9 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR GENE THERAPY, BY REGION 2016โ€“2030 (USD MILLION) 34

TABLE 10 GLOBAL POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 35

TABLE 11 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR HOSPITALS & CLINICS, BY REGION 2016โ€“2030 (USD MILLION) 36

TABLE 12 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION 2016โ€“2030

(USD MILLION) 36

TABLE 13 GLOBAL POMPE DISEASE TREATMENT MARKET, BY REGION 2016โ€“2030 (USD MILLION) 37

TABLE 14 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY REGION 2016โ€“2030 (USD MILLION) 39

TABLE 15 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 39

TABLE 16 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 40

TABLE 17 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 40

TABLE 18 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016โ€“2030 (USD MILLION) 40

TABLE 19 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 41

TABLE 20 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 41

TABLE 21 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 42

TABLE 22 US: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 42

TABLE 23 US: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 42

TABLE 24 US: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 43

TABLE 25 CANADA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 43

TABLE 26 CANADA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 43

TABLE 27 CANADA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 44

TABLE 28 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 44

TABLE 29 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 44

TABLE 30 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 45

TABLE 31 EUROPE: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016โ€“2030 (USD MILLION) 46

TABLE 32 EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 47

TABLE 33 EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 47

TABLE 34 EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 47

TABLE 35 GERMANY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 48

TABLE 36 GERMANY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 48

TABLE 37 GERMANY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 48

TABLE 38 FRANCE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 49

TABLE 39 FRANCE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 49

TABLE 40 FRANCE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 49

TABLE 41 UK: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 50

TABLE 42 UK: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 50

TABLE 43 UK: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 50

TABLE 44 ITALY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 51

TABLE 45 ITALY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 51

TABLE 46 ITALY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 51

TABLE 47 SPAIN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 52

TABLE 48 SPAIN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 52

TABLE 49 SPAIN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 52

TABLE 50 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 53

TABLE 51 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 53

TABLE 52 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 53

TABLE 53 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016โ€“2030 (USD MILLION) 54

TABLE 54 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 55

TABLE 55 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 55

TABLE 56 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 55

TABLE 57 CHINA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 56

TABLE 58 CHINA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 56

TABLE 59 CHINA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 56

TABLE 60 JAPAN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 57

TABLE 61 JAPAN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 57

TABLE 62 JAPAN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 57

TABLE 63 INDIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 58

TABLE 64 INDIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 58

TABLE 65 INDIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 58

TABLE 66 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 59

TABLE 67 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 59

TABLE 68 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 59

TABLE 69 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 60

TABLE 70 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 60

TABLE 71 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 60

TABLE 72 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 61

TABLE 73 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 61

TABLE 74 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 61

TABLE 75 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY REGION 2016โ€“2030 (USD MILLION) 62

TABLE 76 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 62

TABLE 77 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 63

TABLE 78 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 63

TABLE 79 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 63

TABLE 80 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 64

TABLE 81 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 64

TABLE 82 AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016โ€“2030 (USD MILLION) 64

TABLE 83 AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016โ€“2030 (USD MILLION) 65

TABLE 84 AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016โ€“2030 (USD MILLION) 65

TABLE 85 MAJOR PLAYERS IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 66

TABLE 86 COMPETITOR DASHBOARD: GLOBAL POMPE DISEASE TREATMENT MARKET 68

TABLE 87 THE MOST ACTIVE PLAYER IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 69

TABLE 88 EXPANSION 70

TABLE 89 ANNOUNCEMENT 71

TABLE 90 PATENT 71

TABLE 91 DEVELOPMENTS 71

TABLE 92 DEFINITIVE AGREEMENT 71

TABLE 93 AMICUS THERAPEUTICS, INC: FINANCIAL INFORMATION 72

TABLE 94 AMICUS THERAPEUTICS, INC: PRODUCTS/SERVICES OFFERED 72

TABLE 95 AMICUS THERAPEUTICS, INC: KEY DEVELOPMENTS 73

TABLE 96 SANOFI: FINANCIAL INFORMATION 74

TABLE 97 SANOFI : PRODUCTS/SERVICES OFFERED 75

TABLE 98 SANOFI : KEY DEVELOPMENTS 75

TABLE 99 AUDENTES THERAPEUTICS: FINANCIAL INFORMATION 77

TABLE 100 AUDENTES THERAPEUTICS : PRODUCTS/SERVICES OFFERED 77

TABLE 101 AUDENTES THERAPEUTICS: KEY DEVELOPMENTS 78

TABLE 102 OXYRANE : PRODUCTS/SERVICES OFFERED 79

TABLE 103 VALERION THERAPEUTICS : PRODUCTS/SERVICES OFFERED 81

TABLE 104 VALERION THERAPEUTICS: KEY DEVELOPMENTS 81

TABLE 105 AVROBIO, INC.: FINANCIAL INFORMATION 83

TABLE 106 AVROBIO, INC.: PRODUCTS/SERVICES OFFERED 84

TABLE 107 CENTOGENE AG : PRODUCTS/SERVICES OFFERED 85

TABLE 108 CENTOGENE AG : KEY DEVELOPMENTS 85

14 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 12

FIGURE 2 GLOBAL POMPE DISEASE TREATMENT MARKET: STRUCTURE 13

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 20

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF GLOBAL POMPE DISEASE TREATMENT MARKET 22

FIGURE 5 DRIVER IMPACT ANALYSIS 24

FIGURE 6 RESTRAINT IMPACT ANALYSIS 24

FIGURE 7 VALUE CHAIN: GLOBAL POMPE DISEASE TREATMENT MARKET 26

FIGURE 8 PORTERโ€™S FIVE FORCES ANALYSIS: GLOBAL POMPE DISEASE TREATMENT MARKET 28

FIGURE 9 GLOBAL POMPE DISEASE TREATMENT MARKET, BY TYPE 2018 & 2030 (USD MILLION) 30

FIGURE 10 GLOBAL POMPE DISEASE TREATMENT MARKET, BY THERAPY 2018 & 2030 (USD MILLION) 33

FIGURE 11 GLOBAL POMPE DISEASE TREATMENT MARKET, BY END USER 2018 & 2030 (USD MILLION) 35

FIGURE 12 GLOBAL POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%) 38

FIGURE 13 AMERICAS: POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%) 39

FIGURE 14 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET SHARE, BY COUNTRY 2018 (%) 41

FIGURE 15 EUROPE: POMPE DISEASE TREATMENT MARKET SHARE, BY COUNTRY 2018 (%) 46

FIGURE 16 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET SHARE, BYCOUNTRY/ REGION 2018 (%) 54

FIGURE 17 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%) 62

FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS 67

FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE POMPE DISEASE TREATMENT MARKET 69

FIGURE 20 GLOBAL POMPE DISEASE TREATMENT MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 70

FIGURE 21 AMICUS THERAPEUTICS, INC : SWOT ANALYSIS 73

FIGURE 22 SANOFI : SWOT ANALYSIS 76

FIGURE 23 AUDENTES THERAPEUTICS : SWOT ANALYSIS 78

FIGURE 24 OXYRANE : SWOT ANALYSIS 80

FIGURE 25 VALERION THERAPEUTICS : SWOT ANALYSIS 82

FIGURE 26 AVROBIO, INC.: SWOT ANALYSIS 84

FIGURE 27 CENTOGENE AG : SWOT ANALYSIS 86

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.